Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.540
+0.035 (1.00%)
At close: Mar 6, 2026, 4:00 PM EST
3.636
+0.096 (2.70%)
After-hours: Mar 6, 2026, 7:59 PM EST
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Jerome Durso |
Contact Details
Address: 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States | |
| Phone | 240 654 1450 |
| Website | altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jerome Benedict Durso | Chairman, Chief Executive Officer and President |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Andrew Shutterly M.S. | Principal Financial and Accounting Officer and Corporate Controller |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Tony Blandin B.S. | Vice President of Quality and Compliance Management |
| Robin E. Abrams J.D. | General Counsel and Chief Legal Officer |
| Raymond M. Jordt M.B.A. | Chief Business Officer |
| Linda M. Richardson | Chief Commercial Officer |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 6, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 3, 2026 | 8-K | Current Report |
| Jan 30, 2026 | SCHEDULE 13G/A | Filing |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 28, 2026 | 424B5 | Filing |
| Dec 19, 2025 | 8-K | Current Report |
| Dec 5, 2025 | EFFECT | Notice of Effectiveness |